Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib versus platinum doublet chemotherapy as first-line treatment for EGFR uncommon-mutant advanced non-small cell lung cancer
CTR20211262Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Jul 2021; status: active.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211262.